ThomasHerzogMD

Gynecologic Oncology

Professor of Obstetrics & Gynecology, Columbia P&S

Dr. Herzog is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2139 Auburn Ave
Cincinnati, OH 45219
Phone+1 513-585-2323

Fax+1 513-585-4893

Washington University/B-JH/SLCH ConsortiumFellowship, Gynecologic Oncology, 1990 - 1993
TriHealth (Bethesda North and Good Samaritan Hospitals)Residency, Obstetrics and Gynecology, 1986 - 1990
University of Cincinnati College of MedicineClass of 1986

PubMed

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
Karolina A Kilowski, Martin F Dietrich, Joanne Xiu, Yasmine Baca, Andrew Hinton
Gynecologic Oncology. 2024-12-01
Response to Alexandre Andre B A da Costa et al.
Bradley J Monk, Robert L Coleman, Krishnansu S Tewari, Leslie M Randall, Bhavana Pothuri
Gynecologic Oncology. 2024-10-01
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial can...
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, Eirwen M Miller, Zoltan Novak
International Journal of Gynecological Cancer. 2024-09-25

Other

Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer
Herzog TJ
http://www.uptodate.com/contents/adjuvant-therapy-of-early-stage-stage-i-and-ii-epithelial-ovarian-f
UpToDate, Wolters Kluwer Health - 2012-11-13
First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer
Herzog TJ
http://www.uptodate.com/contents/first-line-chemotherapy-for-advanced-stage-iii-or-iv-epithelial-ova
UpToDate, Wolters Kluwer Health - 2013-04-08

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 9th, 2023
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women’s CancerFebruary 24th, 2022
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian CancerMarch 26th, 2021
Join now to see all